Allergan receives FDA approval for new version of dermal filler Juvederm

Allergan receives FDA OK for new Juvederm version

IRVINE, Calif. — Drugmaker Allergan Inc. said Monday regulators have approved Juvederm XC, a new version of its Juvederm dermal filler.

The Irvine, Calif., company said the latest version contains the local anesthetic lidocaine to give patients more comfort during treatment of moderate-to-severe wrinkles and folds, like those that appear around the nose and mouth.

It numbs the treatment area within seconds, which can reduce the need for more anesthetic and lead to less time spent in the doctor’s office, Allergan said.

The Food and Drug Administration approval was based on data from a clinical trial involving 72 patients. The subjects were followed for two weeks after treatment with either Juvederm or the new version, and 93 percent of the patients reported less pain when treated with the new version.

Allergan shares rose 18 cents to $57.68 in late morning trading.